A Securities Fraud Class Action Against Cerevel Therapeutics: Investors Urged to Act Before 2025

Background on Cerevel Therapeutics

As of May 2025, Cerevel Therapeutics Holdings, Inc., listed on the NYSE as ABBV, is embroiled in a pending class action lawsuit filed by Levi & Korsinsky, LLP. This action targets investors who may have suffered losses due to what is alleged to be securities fraud tied to the company's stock performance over a specific period. The lawsuit aims to represent all individuals or entities involved with Cerevel's publicly-traded shares from October 11, 2023, to August 1, 2024.

Summary of the Allegations

The core of the lawsuit revolves around alleged omissions in documentation related to Cerevel's stock offerings. Specifically, the claim suggests that during its secondary offering on October 16, 2023, Cerevel failed to disclose crucial information regarding AbbVie’s interest in acquiring the company at a significantly higher valuation than the offering price. At just $22.81 per share, this price was considerably lower than the $45 per share agreed upon in December 2023 when AbbVie’s acquisition was made public. These omissions reportedly led to stock price manipulation, favoring Cerevel's controlling shareholder, Bain Capital, which seemingly benefited from non-public information at the time of the offering.

Details of the Class Action

Investors who sold or disposed of their shares within the specified timeframe, particularly those affected by the merger discussions, are encouraged to come forward. The complaint outlines how Bain Capital could acquire shares at a depressed price due to Cerevel's lack of transparency, netting them a substantial profit post-announcement of AbbVie’s offer.

If you were holding shares as of January 8, 2024, and are aware of how this affected your investment, you might be entitled to restitution. The court has set a deadline of June 3, 2025, for those interested in becoming lead plaintiffs in this case.

How You Can Participate

Participation in this class action does not require you to bear any costs upfront, as the legal representation will not require out-of-pocket expenses from class members. Levi & Korsinsky assures potential participants that the process is devoid of any financial risks for affected investors. The firm has a proven track record, having secured hundreds of millions for shareholders in previous litigation.

Contact Information

For anyone needing advice or seeking to join the class action, reach out to Joseph E. Levi, Esq. at Levi & Korsinsky via email or phone—details are made available through the firm's official website. Investors must act swiftly, as the fast-approaching deadline is critical for those looking to get involved.

Conclusion

In closing, this lawsuit against Cerevel Therapeutics Holdings, Inc. underscores the importance of transparency within the stock market and shareholder rights. If you're a past investor in Cerevel’s stock, it’s crucial to weigh your options and consider participating in this class action to seek justice and potentially recover losses incurred due to these alleged fraudulent activities. With the legal expertise of Levi & Korsinsky, affected shareholders may find a pathway to recompense for their investments.